24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
LENALIEVA 25 MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | LENALIEVA 25 MG |
|---|---|
| Composition | Lenalidomide Capsules 25mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Btl (30 cap) |
| Country of Origin | India |
LENALIEVA 25 MG (Lenalidomide Capsules 25mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
LENALIEVA 25 MG (Lenalidomide Capsules 25 mg) is a prescription anticancer and immunomodulatory medicine containing Lenalidomide 25 mg, a highly effective treatment used for certain blood cancers and hematological disorders. It belongs to a class of medicines known as Immunomodulatory Agents (IMiDs) that help the body's immune system fight cancer cells while also inhibiting tumor growth and blood vessel formation.
Lenalidomide has become a cornerstone therapy in modern hematology and oncology due to its ability to target cancer cells through multiple mechanisms. It enhances immune cell activity, suppresses abnormal cell growth, and interferes with the development of blood vessels that tumors need to survive and spread.
LENALIEVA 25 MG is widely prescribed for patients with Multiple Myeloma, Myelodysplastic Syndromes (MDS) associated with deletion 5q abnormalities, Mantle Cell Lymphoma (MCL), and certain other blood-related cancers. It may be used alone or in combination with other anticancer therapies depending on the patient's condition and treatment plan.
The medicine is often recommended for long-term treatment and maintenance therapy to help control disease progression, improve treatment outcomes, and support prolonged remission in eligible patients.
LENALIEVA 25 MG is commonly prescribed for:
Manufactured according to stringent pharmaceutical quality standards, LENALIEVA 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenalidomide therapy require regular blood tests, complete blood count monitoring, kidney function assessments, and clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy in blood cancer management, LENALIEVA 25 MG has become an essential medicine in modern oncology and hematology practice worldwide.
LENALIEVA 25 MG (Lenalidomide Capsules 25 mg) is primarily used for the treatment and management of specific blood cancers and bone marrow disorders.
The medicine is widely prescribed for newly diagnosed and relapsed multiple myeloma patients.
Lenalidomide may be used as maintenance treatment following successful initial therapy.
The medicine helps manage certain forms of MDS, particularly those associated with deletion 5q abnormalities.
Doctors may prescribe Lenalidomide for patients with relapsed or refractory mantle cell lymphoma.
The medicine may be incorporated into treatment protocols for selected blood cancers.
Lenalidomide helps delay disease progression and improve treatment outcomes.
The medicine is frequently used alongside corticosteroids and other anticancer treatments.
Lenalidomide belongs to a class of medicines known as Immunomodulatory Agents (IMiDs).
LENALIEVA works by:
This multi-targeted mechanism helps improve outcomes in patients with blood cancers and related disorders.
Like all medicines, LENALIEVA 25 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are frequently reported during treatment.
The medicine may reduce white blood cells, red blood cells, and platelet counts.
Digestive disturbances such as constipation may occur.
Some patients may experience diarrhea during treatment.
Mild to moderate nausea may develop.
Muscle pain or cramping may occur.
Skin reactions may develop in some individuals.
Patients may occasionally experience dizziness.
Reduced appetite may affect nutritional intake.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of LENALIEVA 25 MG (Lenalidomide Capsules 25 mg) should always be determined by a qualified healthcare professional.
Treatment recommendations vary according to the specific disease being treated.
Lenalidomide dosage may require adjustment in patients with kidney impairment.
Regular monitoring helps guide dosage decisions.
Doctors may modify treatment according to effectiveness and tolerance.
Concurrent medicines may influence treatment plans and dosage schedules.
Before starting treatment, inform your doctor if you have:
Lenalidomide can cause severe birth defects and should never be used during pregnancy. Effective contraception and strict pregnancy prevention measures are required during treatment.
Patients should also disclose all prescription medications, supplements, vitamins, and herbal products they are currently taking to avoid potential drug interactions.
It is used for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, and certain blood-related cancers.
Lenalidomide is an immunomodulatory medicine that helps the immune system fight cancer cells and slows tumor growth.
It is generally classified as an immunomodulatory anticancer medicine rather than traditional chemotherapy.
Yes. It is one of the most commonly prescribed medicines for multiple myeloma treatment and maintenance therapy.
Yes. It may reduce white blood cells, red blood cells, and platelet counts, requiring regular monitoring.
Yes. Lenalidomide can cause serious birth defects, and strict pregnancy prevention measures are essential.
Yes. Routine blood tests, kidney function assessments, and clinical evaluations are necessary throughout treatment.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology treatment.